Valion Bio Statistics
Total Valuation
Valion Bio has a market cap or net worth of $2.70 million. The enterprise value is $12.49 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Valion Bio has 3.14 million shares outstanding. The number of shares has increased by 324.89% in one year.
| Current Share Class | 3.14M |
| Shares Outstanding | 3.14M |
| Shares Change (YoY) | +324.89% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.28% |
| Owned by Institutions (%) | 15.07% |
| Float | 3.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.23 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 1.54.
| Current Ratio | 3.31 |
| Quick Ratio | 2.76 |
| Debt / Equity | 1.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.31 |
Financial Efficiency
Return on equity (ROE) is -182.22% and return on invested capital (ROIC) is -48.80%.
| Return on Equity (ROE) | -182.22% |
| Return on Assets (ROA) | -36.18% |
| Return on Invested Capital (ROIC) | -48.80% |
| Return on Capital Employed (ROCE) | -34.14% |
| Weighted Average Cost of Capital (WACC) | 5.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$261,115 |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.87% in the last 52 weeks. The beta is 1.87, so Valion Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -79.87% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 368,182 |
Short Selling Information
The latest short interest is 245,772, so 7.83% of the outstanding shares have been sold short.
| Short Interest | 245,772 |
| Short Previous Month | 63,926 |
| Short % of Shares Out | 7.83% |
| Short % of Float | 8.17% |
| Short Ratio (days to cover) | 1.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.16M |
| Pretax Income | -12.85M |
| Net Income | -13.58M |
| EBITDA | -12.15M |
| EBIT | -12.16M |
| Earnings Per Share (EPS) | -$7.91 |
Full Income StatementBalance Sheet
The company has $7.22 million in cash and $17.03 million in debt, with a net cash position of -$9.82 million or -$3.13 per share.
| Cash & Cash Equivalents | 7.22M |
| Total Debt | 17.03M |
| Net Cash | -9.82M |
| Net Cash Per Share | -$3.13 |
| Equity (Book Value) | 11.06M |
| Book Value Per Share | 3.84 |
| Working Capital | 6.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.12 million and capital expenditures -$45,000, giving a free cash flow of -$11.17 million.
| Operating Cash Flow | -11.12M |
| Capital Expenditures | -45,000 |
| Depreciation & Amortization | 8,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.17M |
| FCF Per Share | -$3.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
